Yazar "Ogan, Nalan" için listeleme
-
Carotid intima-media thickness in chronic obstructive pulmonary disease and survival: A multicenter prospective study
Gülbaş, Gazi; Turan, Onur; Sarıoğlu, Nurhan; Diken, Özlem Ercen; Ogan, Nalan; Kadıoğlu, Esra Ekbiç; Kurtipek, Ercan; Bozkuş, Fulsen (Wiley, 2019)Introduction Chronic obstructive pulmonary disease (COPD) is associated with increased cardiovascular morbidity and mortality. Carotid intima-media thickness (CIMT) is a noninvasive method assessing atherosclerosis. Objective ... -
Chronic obstructive pulmonary disease phenotypes in Turkey: the COPET study—a national, multicenter cross-sectional observational study
Hoca, Nevin Taci; Sarıoğlu, Nurhan; Mirici, Nihal Arzu; Süerdem, Mecit; Çalıkoğlu, Mukadder; Ogan, Nalan; Bozkus, Fulsen (2022)Background/aim: While mortality rates decrease in many chronic diseases, it continues to increase in COPD. This situation has led to the need to develop new approaches such as phenotypes in the management of COPD. We aimed ... -
Disease history of patients with COPD
Suerdem, Mecit; Sarıoğlu, Nurhan; Ogan, Nalan; Arslan, Sertaç; Yıldırım, Gülfem; Diken, Özlem Ercen; Bozkuş, Fulsen; Gülbaş, Gazi; Demirci, Nilgün Yılmaz (Kare Publ, 2022)BACKGROUND AND AIM: This study aimed to obtain real-life data of patients diagnosed with chronic obstructive pulmonary disease (COPD) at least one year ago, including smoking history, inhaler device training, and the ... -
Long acting B-2 agonists (LABA) or anticholinergics (LAMA): Which one is more efficient in Group A COPD patients?
Turan, Muzaffer Onur; Ogan, Nalan; Bozkuş, Fulsen; Sarıoğlu, Nurhan; Turan, Pakize Ayşe; Satıcı, Celal (European Respiratory Soc Journals Ltd, 2021)Introduction: Long-acting anticholinergic (LAMA) or beta-2 agonists (LABA) for symptom control in symptomatic group A COPD patients in GOLD guideline, however, there is no mention of priority or superiority between the two ... -
Long-acting B-2 agonists (LABA) or long-acting muscarinic antagonists (LAMA): Which one may be the first option in group A COPD patients?
Turan, Muzaffer Onur; Ogan, Nalan; Bozkuş, Fulsen; Sarıoglu, Nurhan; Turan, Pakize Ayşe; Satıcı, Celal (Springer Heidelberg, 2024)IntroductionLong-acting muscarinic antagonists (LAMA) or beta-2 agonists (LABA) have been recommended for symptom control in group A COPD patients as a first-line bronchodilator treatment in GOLD guidelines. However, there ... -
The value of preoperative pulmonary assessment in predicting postoperative pulmonary complications
Diken, Özlem Erçen; Fazlıoğlu, Nevin; Sarıoğlu, Nurhan; Ogan, Nalan; Yılmaz, Nafiye; Tanrıverdi, Hakan; Şengül, Aysun; Demir, Emre; Turna, Akif; Mirici, Arzu (Wolters Kluwer Medknow Publications, 2019)OBJECTIVE: We aimed to determine the preoperative parameters that may predict postoperative pulmonary complications (POPCs) and the value of some current practical indexes in predicting POPCs. MATERIALS and METHODS: Our ...
